journal article·2024-11Open access

Highly Efficient Synergistic Chemotherapy and Magnetic Resonance Imaging for Targeted Ovarian Cancer Therapy Using Hyaluronic Acid‐Coated Coordination Polymer Nanoparticles

Guang Li, Shengying Shi, Jingxiu Tan, Lijuan He, Qiwen Liu, Feng Fang, Huijiao Fu, Min Zhong, Ziyi Mai, Rui Sun, Kun Liu, Zhenzhen Feng, Peiqin Liang, Zhiqiang Yu, Xuefeng Wang

Advanced Science· Volume 11· Issue 41

Abstract

Abstract The diagnosis and treatment of ovarian cancer (OC) are still a grand challenge, more than 70% of patients are diagnosed at an advanced stage with a dismal prognosis. Magnetic resonance imaging (MRI) has shown superior results to other examinations in preoperative assessment, while cisplatin‐based chemotherapy is the first‐line treatment for OC. However, few previous studies have brought together the two rapidly expanding fields. Here a technique is presented using cisplatin prodrug (Pt‐COOH), Fe3+, and natural polyphenols (Gossypol) to construct the nanoparticles (HA@PFG NPs) that have a stable structure, controllable drug release behavior, and high drug loading capacity. The acidic pH values in tumor sites facilitate the release of Fe3+, Pt‐COOH, and Gossypol from HA@PFG NPs. Pt‐COOH with GSH consumption and cisplatin‐based chemotherapy plus Gossypol with pro‐apoptotic effects displays a synergistic effect for killing tumor cells. Furthermore, the release of Fe3+ at the tumor sites promotes ferroptosis and enables MRI imaging of OC. In the patient‐derived tumor xenograft (PDX) model, HA@PFG NPs alleviate the tumor activity. RNA sequencing analysis reveals that HA@PFG NPs ameliorate OC symptoms mainly through IL‐6 signal pathways. This work combines MRI imaging with cisplatin‐based chemotherapy, which holds great promise for OC diagnosis and synergistic therapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Obstetrics and Gynecology The Third Affiliated Hospital Southern Medical University Guangzhou 510630 China

Department of Gynecological Oncology and Cervical Lesions Hunan Provincial Maternal and Child Health Care Hospital Changsha 410013 China

Department of Nursing Nanfang Hospital Southern Medical University Guangzhou 510000 China

Department of Pharmacy The First Affiliated Hospital of Shenzhen University Shenzhen Second People's Hospital Shenzhen 518035 China

Department of Laboratory Medicine Dongguan Institute of Clinical Cancer Research Affiliated Dongguan Hospital Southern Medical University Dongguan 523018 China

School of Pharmacy Guangdong Medical University Dongguan 523808 China

Funding

Red de Salud Materno Infantil y del Desarrollo

References (51)

Show source-provided references
1. 10.1038/s41419-022-05000-710.1038/s41419-022-05000-7 ↗
2. 10.7150/thno.4487110.7150/thno.44871 ↗
3. 10.1016/j.mtbio.2022.10021810.1016/j.mtbio.2022.100218 ↗
4. 10.3390/cancers1415371910.3390/cancers14153719 ↗
5. 10.1186/s12951-022-01676-310.1186/s12951-022-01676-3 ↗
6. 10.1038/s41416-020-0878-710.1038/s41416-020-0878-7 ↗
7. 10.7150/thno.7169310.7150/thno.71693 ↗
8. 10.1016/j.biomaterials.2020.12023410.1016/j.biomaterials.2020.120234 ↗
9. 10.1002/advs.20210085010.1002/advs.202100850 ↗
10. 10.3390/pharmaceutics1405100010.3390/pharmaceutics14051000 ↗
11. 10.1038/s41467-020-14693-310.1038/s41467-020-14693-3 ↗
12. 10.1016/j.bioactmat.2021.12.01110.1016/j.bioactmat.2021.12.011 ↗
13. 10.1186/s12951-022-01416-710.1186/s12951-022-01416-7 ↗
14. 10.1016/j.apsb.2021.10.00710.1016/j.apsb.2021.10.007 ↗
15. 10.1002/advs.20220226010.1002/advs.202202260 ↗
16. 10.1002/adma.20210059910.1002/adma.202100599 ↗
17. 10.1038/s41551-021-00728-710.1038/s41551-021-00728-7 ↗
18. 10.1016/j.nantod.2022.10145910.1016/j.nantod.2022.101459 ↗
19. 10.1021/acsnano.0c0619010.1021/acsnano.0c06190 ↗
20. Xiang J. · Nano Lett. · 2022
21. 10.1002/adma.20220857110.1002/adma.202208571 ↗
22. 10.1002/adfm.20220284810.1002/adfm.202202848 ↗
23. 10.1002/adma.20200735610.1002/adma.202007356 ↗
24. 10.1016/j.ccr.2021.21405910.1016/j.ccr.2021.214059 ↗
25. 10.1021/acsnano.7b0685210.1021/acsnano.7b06852 ↗
26. 10.1039/D1CS01165K10.1039/D1CS01165K ↗
27. 10.1002/adma.20230314910.1002/adma.202303149 ↗
28. 10.1002/adfm.20221342510.1002/adfm.202213425 ↗
29. Wang G. · Nat. Commun. · 2021 · 12
30. 10.1016/j.biomaterials.2017.11.00110.1016/j.biomaterials.2017.11.001 ↗
31. 10.1002/adfm.20211316810.1002/adfm.202113168 ↗
32. 10.1002/adfm.20180558210.1002/adfm.201805582 ↗
33. 10.1021/acsnano.3c0699110.1021/acsnano.3c06991 ↗
34. 10.31635/ccschem.022.20220256510.31635/ccschem.022.202202565 ↗
35. 10.2174/092986732466617052312365510.2174/0929867324666170523123655 ↗
36. 10.1021/jm100169810.1021/jm1001698 ↗
37. Nakamura T. · Nat. Commun. · 2017 · 8
38. 10.1002/adfm.20210095410.1002/adfm.202100954 ↗
39. 10.1007/s12274-022-4239-010.1007/s12274-022-4239-0 ↗
40. 10.1016/j.biomaterials.2018.07.02110.1016/j.biomaterials.2018.07.021 ↗
41. 10.1002/advs.20180101210.1002/advs.201801012 ↗
42. 10.1002/adfm.20200375710.1002/adfm.202003757 ↗
43. 10.1007/s11095-011-0498-210.1007/s11095-011-0498-2 ↗
44. 10.1038/s41419-023-05716-010.1038/s41419-023-05716-0 ↗
45. Chen X. · J. Exp. Med. · 2021 · 6 · 218
46. 10.1002/hep.3078010.1002/hep.30780 ↗
47. 10.1172/JCI20042094510.1172/JCI200420945 ↗
48. 10.1080/21655979.2021.196415810.1080/21655979.2021.1964158 ↗
49. 10.1016/j.freeradbiomed.2022.01.02010.1016/j.freeradbiomed.2022.01.020 ↗
50. 10.1021/acsnano.2c0176410.1021/acsnano.2c01764 ↗
51. 10.1016/j.nantod.2019.10080010.1016/j.nantod.2019.100800 ↗